人工智能驱动的生活方式干预与人工指导在糖尿病预防计划中的比较:一项随机临床试验
这项3期平行组实用性非劣效随机临床试验纳入368例糖尿病前期合并超重或肥胖成人,比较转介至纯人工智能主导或人工教练主导的糖尿病预防计划生活方式干预。12个月时,人工智能组31.7%与人工组31.9%达到主要复合终点,风险差-0.2%(单侧95%CI -8.2%),满足非劣效标准。
要点
- 在糖尿病前期合并超重或肥胖成人中,转介至纯人工智能主导的糖尿病预防计划在12个月复合终点上非劣效于转介至人工教练主导的糖尿病预防计划。
- 人工智能组58/183例(31.7%)与人工组59/185例(31.9%)达到主要复合终点,风险差-0.2%(单侧95%CI -8.2%)。
- 转介后人工智能组171/183例(93.4%)启动干预,人工组153/185例(82.7%)启动干预。
核心结论
- 在糖尿病前期合并超重或肥胖成人中,转介至全自动人工智能主导的糖尿病预防计划在达到基于体重减轻、体力活动和HbA1c的复合终点方面非劣效于转介至人工教练主导的糖尿病预防计划。
研究设计与样本
- 这项3期、平行组、实用性、非劣效随机临床试验于2021年10月11日至2024年12月16日(末次随访)在美国马里兰州巴尔的摩和宾夕法尼亚州雷丁的2个临床中心开展。
- 共纳入368例18岁及以上糖尿病前期合并超重或肥胖成人,按1:1随机分配至转介至通过移动应用和蓝牙数字秤提供的人工智能驱动糖尿病预防计划生活方式干预组或转介至远程人工教练主导的糖尿病预防计划生活方式干预组。
- 两种干预均由研究团队之外独立实施,持续12个月。
主要发现
- 主要终点为整个研究期间维持HbA1c低于6.5%且达到以下任一:体重减轻至少5%、体重减轻至少4%且每周体力活动至少150分钟(通过活动记录仪评估)、或12个月时HbA1c绝对降低至少0.2个百分点。
- 人工智能组58/183例(31.7%)与人工组59/185例(31.9%)达到主要终点,风险差-0.2%(单侧95%CI -8.2%),满足非劣效标准。
- 转介后人工智能组171/183例(93.4%)启动干预,人工组153/185例(82.7%)启动干预。
- 结果在复合终点的各单独组分及敏感性分析中一致。
关键数值与推荐
- 非劣效性预设判定标准为风险差的单侧95%CI下限不低于-15%。
- 主要终点复合标准:维持HbA1c低于6.5%且达到体重减轻至少5%、或体重减轻至少4%加每周体力活动至少150分钟、或HbA1c绝对降低至少0.2个百分点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prediabetes is common, yet evidence-based lifestyle interventions are underutilized. OBJECTIVE: To determine whether referral to an exclusively artificial intelligence (AI)-led lifestyle intervention based on the Diabetes Prevention Program (DPP) is noninferior to referral to a human-led DPP in achieving recommended thresholds for weight loss, hemoglobin A1c (HbA1c) reduction, and weekly physical activity among adults with prediabetes and overweight or obesity. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, parallel-group, pragmatic, noninferiority randomized clinical trial was conducted from October 11, 2021, to December 16, 2024 (last follow-up) at 2 US clinical sites in Baltimore, Maryland, and Reading, Pennsylvania. Adults 18 years or older with prediabetes and overweight or obesity were enrolled. INTERVENTIONS: Participants were randomized in a 1:1 ratio to receive either a referral to an AI-powered DPP lifestyle intervention delivered via a mobile app and Bluetooth-enabled digital scale or a referral to a human coach-led DPP lifestyle intervention delivered remotely. Both interventions were delivered independently of the study team over a 12-month period. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of maintaining an HbA1c less than 6.5% throughout the study and achievement of at least 5% weight loss, at least 4% weight loss plus at least 150 minutes of weekly physical activity (assessed with actigraphy), or an absolute reduction in HbA1c of at least 0.2 percentage points at 12 months. Noninferiority of referral to the AI-led DPP compared with referral to the human-led DPP was prespecified to be determined if the 1-sided 95% CI lower boundary of the risk difference did not cross -15%. RESULTS: A total of 368 participants were included (median [IQR] age, 58 [50-65] years; 71% were female, 27% were Black, 6% were Hispanic, and 61% were White; median [IQR] BMI, 32.3 [28.5-37.1]). After referral, 171 of 183 participants (93.4%) initiated the AI-led DPP and 153 of 185 (82.7%) initiated the human-led DPP. The primary outcome was achieved by 58 of 183 participants (31.7%) in the AI-led DPP group and 59 of 185 (31.9%) in the human-led DPP group (risk difference, -0.2% [1-sided 95% CI, -8.2%]), meeting the criterion for noninferiority. Findings were consistent across individual components of the composite end point and in sensitivity analyses. CONCLUSIONS AND RELEVANCE: Among adults with prediabetes and overweight or obesity, referral to a fully automated AI-led DPP was noninferior to referral to a human-led DPP in achieving a composite outcome based on weight reduction, physical activity, and HbA1c. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05056376.
引用
- Mathioudakis N, Lalani B, Abusamaan MS, et al. An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial. JAMA. 2025. PMID: 41144242. doi:10.1001/jama.2025.19563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。